Inventor
Samuel Wadsworth
Inventor
Shrewsbury, MA, US
Overview
Patents· 21 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C12Nprimary
C12NMicroorganisms or enzymes26%
A61KPreparations for medical, dental or toiletry purposes24%
C07KPeptides24%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations14%
A01KAnimal husbandry6%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture4%
C12YEnzymes1%
PatentTitleYear
11,084,864Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof202110,920,245Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders202110,640,771Compositions and methods for treating and preventing macular degeneration202010,183,983Nucleic acids encoding fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof20199,890,394'Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders'20189,815,892'Multimeric constructs'20179,637,534'Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof'20178,658,602'Multimeric constructs'20147,928,072'Multimeric constructs'20117,615,537'Methods for treating blood coagulation disorders'20097,312,324'Regulatory elements for delivery to the liver'20076,632,670'AAV vectors for gene therapy'20036,541,245'Adenoviral helper vectors'20036,303,371'Method of purified rAAV vector production in non-human cell line transfected with cocksackie and adenovirus receptor'20016,287,857'Nucleic acid delivery vehicles'20016,020,191'Adenoviral vectors capable of facilitating increased persistence of transgene expression'20005,824,544'Adenovirus vectors for gene therapy'19985,811,633'Transgenic mouse expressing APP.sub.770'19985,720,936'Transgenic mouse assay for compounds affecting amyloid protein processing'19985,707,618'Adenovirus vectors for gene therapy'19985,604,131'cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions'1997Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1997–1998Patents assigned to ATHENA NEUROSCIENCES INC (2)· patent assignee history
1997–2021Based in Shrewsbury, MA, US· patent location history
1998–2021Patents assigned to GENZYME CORP (17)· patent assignee history
2014–2018Patents assigned to WADSWORTH SAMUEL (2)· patent assignee history
2014Patents assigned to GenzymeCorporation (1)· patent assignee history
2017Based in Cambridge, MA, US· patent location history
2018Patents assigned to ORIORDAN CATHERINE (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| GENZYME CORP | 17 | 1998–2021 |
| ATHENA NEUROSCIENCES INC | 2 | 1997–1998 |
| WADSWORTH SAMUELself | 2 | 2014–2018 |
| GenzymeCorporation | 1 | 2014 |
| ORIORDAN CATHERINE | 1 | 2018 |
Locations
| Location | Patents | Span |
|---|---|---|
| Shrewsbury, Massachusetts, US | 20 | 1997–2021 |
| Cambridge, Massachusetts, US | 1 | 2017 |